Chae YK - Search Results

1

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.

Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Kim ES, et al. Among authors: chae yk. Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14. Nat Med. 2022. PMID: 35422531 Free PMC article. Clinical Trial.

2

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ. Chae YK, et al. Sci Rep. 2018 Jan 18;8(1):1023. doi: 10.1038/s41598-018-19454-3. Sci Rep. 2018. PMID: 29348685 Free PMC article.

3

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).

Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K, Cruz M. Chae YK, et al. Sci Rep. 2018 Feb 13;8(1):2918. doi: 10.1038/s41598-018-21061-1. Sci Rep. 2018. PMID: 29440769 Free PMC article.

4

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.

Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F. Chae YK, et al. Clin Lung Cancer. 2019 Mar;20(2):88-96.e6. doi: 10.1016/j.cllc.2018.09.008. Epub 2018 Sep 25. Clin Lung Cancer. 2019. PMID: 30425022

5

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ. Chae YK, et al. Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13. Oncologist. 2019. PMID: 30867242 Free PMC article.

6

Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases.

Wong WB, Wu N, Yang E, Davies J, Chae YK. Wong WB, et al. Among authors: chae yk. J Oncol Pract. 2019 Oct;15(10):e878-e887. doi: 10.1200/JOP.19.00166. Epub 2019 Sep 11. J Oncol Pract. 2019. PMID: 31509482

7

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G. Park W, et al. Among authors: chae yk. Br J Cancer. 2020 Feb;122(3):340-347. doi: 10.1038/s41416-019-0643-y. Epub 2019 Nov 25. Br J Cancer. 2020. PMID: 31761899 Free PMC article.

8

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: chae yk. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.

9

The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM. Oh MS, et al. Among authors: chae yk. Clin Lung Cancer. 2021 Jan;22(1):e57-e62. doi: 10.1016/j.cllc.2020.07.016. Epub 2020 Aug 5. Clin Lung Cancer. 2021. PMID: 32900613 Free PMC article.

10

Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).

Kim Y, Vagia E, Viveiros P, Kang CY, Lee JY, Gim G, Cho S, Choi H, Kim L, Park I, Choi J, Chae YK. Kim Y, et al. Among authors: chae yk. Cancer Immunol Immunother. 2021 Apr;70(4):961-965. doi: 10.1007/s00262-020-02703-8. Epub 2020 Oct 21. Cancer Immunol Immunother. 2021. PMID: 33084943 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

237 results

Search Page